###
中国临床研究:2026,39(8):1283-1287
本文二维码信息
码上扫一扫!
免疫检查点抑制剂致内分泌免疫相关不良反应的预测生物标志物研究
(南京医科大学第一附属医院内分泌科, 江苏 南京 210029)
Biomarkers for predicting endocrine immune-related adverse events induced by immune checkpoint inhibitors
(Department of Endocrinology,the First Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu 210029,China)
摘要
本文已被:浏览 262次   下载 189次
投稿时间:2025-11-26   网络发布日期:2026-08-25
中文摘要: 免疫检查点抑制剂(ICIs)的应用为肿瘤治疗带来了革命性突破,但其引发的内分泌免疫相关不良反应(irAEs)已成为影响患者生存质量与治疗持续性的关键临床难题。此类不良反应可累及垂体、甲状腺、肾上腺及胰腺,其发生机制涉及遗传易感性、自身免疫激活及免疫细胞浸润等多重因素。本综述立足于内分泌学科特点,系统阐述了针对上述靶腺体损伤的预测生物标志物研究进展,重点围绕人类白细胞抗原(HLA)基因型、器官特异性自身抗体、血液学指标(如嗜酸性粒细胞)及激素动态变化等核心标志物展开论述,明确其预测价值与局限性。当前研究面临的主要挑战包括标志物验证不足、缺乏标准化检测体系以及种族异质性等。未来方向应聚焦于大规模前瞻性队列验证、复合预测模型构建及中国人群特异性研究,旨在为临床早期识别高危患者、制定个体化监测与干预策略提供循证依据,最终实现肿瘤免疫治疗的精准安全管理。
Abstract:The application of immune checkpoint inhibitors(ICIs)has brought a revolutionary breakthrough in tumor treatment,but the induced endocrine immune-related adverse events(irAEs)have become a key clinical challenge affecting patients'quality of life and treatment continuity. These adverse events involve the pituitary,thyroid,adrenal glands,and pancreas,with pathogenesis involving multiple factors such as genetic susceptibility,autoimmune activation,and immune cell infiltration. Based on the characteristics of endocrinology,this review systematically elaborates on the research progress in predictive biomarkers for injuries to these target glands,and focuses on key biomarkers including human leukocyte antigen (HLA)genotypes,organ - specific autoantibodies,hematological parameters(e.g.,eosinophils),and dynamic hormonal changes,clarifying their predictive value and limitations. The main challenges currently encountered include insufficient biomarker validation,lack of standardized detection systems,and racial heterogeneity. Future directions should focus on large - scale prospective cohort validation,construction of composite predictive models,and specific research among Chinese populations,aiming to provide evidence-based references for the early identification of high - risk patients and the development of personalized monitoring and intervention strategies,ultimately achieving precise and safe tumor immunotherapy.
文章编号:     中图分类号:R730.51    文献标志码:A
基金项目:江苏省卫生健康委员会医学研究项目(k2024057)
附件
引用文本:
王秋忆, 郑旭琴.免疫检查点抑制剂致内分泌免疫相关不良反应的预测生物标志物研究[J].中国临床研究,2026,39(8):1283-1287.

用微信扫一扫

用微信扫一扫